Department of Dermatology.
Eur J Dermatol. 2013 Jul-Aug;23(4):467-70. doi: 10.1684/ejd.2013.2029.
Technetium-99m-sestamibi (MIBI) is a radiopharmaceutical that has well-known tumor-seeking properties. We evaluated the correlation between Breslow thickness and MIBI uptake by cutaneous melanoma (CM).
Patients with suspicious melanocytic lesions received intravenous injections of 740-1,110 Mbq of MIBI. Using a gamma probe, the number of radioactive counts in the skin was considered to determinate the MIBI uptake intensity. SPECT imaging of the lesion site and respective lymph node region was obtained.
There was a strong positive correlation between MIBI uptake intensity and Breslow thickness (rs = 0.74, P = 0.003). There was a statistically significant difference (P <0.001) between lesions with Breslow thickness <1 mm (MIBI uptake intensity = 1.23 ± 0.28 radioactive counts) and Breslow thickness >1 mm (MIBI uptake intensity = 2.32 ± 0.32 radioactive counts).
The possibility of correlating MIBI uptake intensity with Breslow categories may facilitate surgical procedures, reducing morbidity and costs.
锝-99m-甲氧基异丁基异腈（MIBI）是一种放射性药物，具有众所周知的肿瘤寻迹特性。我们评估了皮肤黑色素瘤（CM）的 Breslow 厚度与 MIBI 摄取之间的相关性。
有可疑黑色素瘤病变的患者接受 740-1110MBq 的 MIBI 静脉注射。使用伽马探针，皮肤中的放射性计数数量被认为是确定 MIBI 摄取强度的指标。对病变部位和相应的淋巴结区域进行 SPECT 成像。
MIBI 摄取强度与 Breslow 厚度之间存在很强的正相关关系（rs = 0.74，P = 0.003）。Breslow 厚度<1mm（MIBI 摄取强度=1.23±0.28 放射性计数）和 Breslow 厚度>1mm（MIBI 摄取强度=2.32±0.32 放射性计数）之间存在统计学差异（P<0.001）。
MIBI 摄取强度与 Breslow 分类之间的相关性可能有助于手术过程，降低发病率和成本。
